They concluded that MALAT1 could promote the progression of NSCLC via miR-200a-3p/PD-L1 axis, which indicated that high expression of MALAT1 in NSCLC might enhance resistance to anti-PD-1 immunotherapy (Wei et al., 2019a). Here, MALAT1 is linked to non-small cell lung carcinoma.